Lypressin

Vasopressin Analogue (nonapeptide)Rx: PrescriptionCompound: Withdrawn

Also known as: 8-Lysine vasopressin, Diapid, LVP, Lysine vasopressin

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Lypressin (8-lysine vasopressin) is a synthetic analogue of the endogenous antidiuretic hormone vasopressin, used historically for the treatment of diabetes insipidus. It was administered intranasally as a nasal spray. It has largely been replaced by desmopressin (DDAVP), which has a longer duration of action and fewer vasopressor side effects.

Mechanism of Action

Synthetic analogue of lysine vasopressin that acts on V1 and V2 vasopressin receptors. V2 receptor activation in renal collecting ducts increases water reabsorption via aquaporin channels, reducing urine output. V1 receptor activation causes vasoconstriction.

Routes of Administration

IntravenousNasalSubcutaneous

Goals & Uses

  • Treatment of central diabetes insipidusEndocrine / RenalModerate
  • Reduction of polydipsiaSymptomatic ReliefModerate
  • Reduction of polyuriaSymptomatic ReliefModerate

Contraindications

  • Hypersensitivity to vasopressin or analoguesImmunologicHigh
  • HypertensionCardiovascularModerate
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data
  • Coronary artery diseaseCardiovascularHigh
  • Nephrogenic diabetes insipidusRenalHigh

Adverse Effects

  • Nasal congestion and rhinitisLocal / NasalCommon
  • Hyponatremia / water intoxicationMetabolicRare
  • HeadacheNeurologicUncommonPain in the head or upper neck
  • Abdominal crampsGastrointestinalCommon
  • Pallor and vasoconstrictionCardiovascularUncommon
  • Angina pectorisCardiovascularRare

Drug Interactions

  • Tricyclic antidepressantsLow
  • NSAIDsLowMay increase renal risk in susceptible patients
  • ChlorpropamideModerate
  • LithiumModerate

Population Constraints

  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Patients with chronic renal diseaseRenal ImpairmentRelative

Regulatory Status

  • European UnionUnknownNot known to be currently marketed or approved in the EU; desmopressin is the standard of care.
  • United StatesWithdrawnApproved: Central diabetes insipidusPreviously marketed as Diapid nasal spray; withdrawn from the US market. Replaced by desmopressin (DDAVP).
  • United KingdomUnknownNot currently listed as an approved product in the UK; desmopressin is preferred.

Previously approved in the United States (brand name Diapid) as a nasal spray for diabetes insipidus but has since been withdrawn from the US market. Not currently approved or marketed in most major jurisdictions; replaced by desmopressin.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack